Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01491035 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder
A Phase 2 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT01491035 is a Phase 2 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 48 participants.
The verdict
NCT01491035, a Phase 2 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
The objective of the study is to evaluate the pharmacokinetics of vortioxetine and its metabolites in connection with multiple oral dosing in child and adolescent patients with a DSM-IV-TR diagnosis of Depressive or Anxiety Disorder
Interventions
- DRUG Vortioxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2012-04 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01491035
The ClinicalTrials.gov registry entry for NCT01491035 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vortioxetine is the first listed.
NCT01491035 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01491035 about?
NCT01491035 is a clinical study titled "Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder". The objective of the study is to evaluate the pharmacokinetics of vortioxetine and its metabolites in connection with multiple oral dosing in child and adolescent patients with a DSM-IV-TR diagnosis of Depressive or Anxiety Disorder
What is the current status of trial NCT01491035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2012-04. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01491035?
The interventions under investigation include: Vortioxetine (DRUG).
Who is sponsoring clinical trial NCT01491035?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.